<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study examined the efficacy and tolerability of docetaxel(DOC)in combination with <z:chebi fb="0" ids="47898">epirubicin</z:chebi>(EPI)as the first-line treatment for patients with advanced and recurrent <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 56 female patients with metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> not previously treated for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> received DOC(60mg/m²)and EPI(60mg/m2)on day 1 every 3 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>The patient characteristics included a median age of 53 years </plain></SENT>
<SENT sid="3" pm="."><plain>Advanced disease was present in 86% of patients, and <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> was found in 14%; 3 or more metastatic sites had been diagnosed in 38% of patients, and 59% patients were ER+ </plain></SENT>
<SENT sid="4" pm="."><plain>The median number of courses administered was 6 </plain></SENT>
<SENT sid="5" pm="."><plain>The median dose intensity was 18 </plain></SENT>
<SENT sid="6" pm="."><plain>7mg/m²week for DOC and EPI, and the relative dose intensities were 93 </plain></SENT>
<SENT sid="7" pm="."><plain>5%and 93 </plain></SENT>
<SENT sid="8" pm="."><plain>3%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The clinical responses included a complete response in 5%, a partial response in 54%, and stable disease in 33% of patients, with a disease control rate of 92% </plain></SENT>
<SENT sid="10" pm="."><plain>The progression-free survival was 78 </plain></SENT>
<SENT sid="11" pm="."><plain>3%, and the overall survival was 91 </plain></SENT>
<SENT sid="12" pm="."><plain>9% at 1 year </plain></SENT>
<SENT sid="13" pm="."><plain>Grade 3/4 toxicities included <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 82%, <z:hpo ids='HP_0001882'>leukopenia</z:hpo> in 71%, febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 16%, <z:hpo ids='HP_0002039'>anorexia</z:hpo> in 9%, and <z:hpo ids='HP_0001903'>anemia</z:hpo> in 7%of the patients </plain></SENT>
<SENT sid="14" pm="."><plain>Neither <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> nor toxic <z:hpo ids='HP_0011420'>death</z:hpo> occurred </plain></SENT>
<SENT sid="15" pm="."><plain>The D and E combination with doses of 60mg/m2 is an active and generally well-tolerated regimen that can be used as first-line chemotherapy for patients with metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>